-
Patients’ and caregivers’ “lived experience” crucial in CHS submissions on product access
It’s an exciting time in care for people with bleeding disorders. In recent years, a number of novel therapies have come through clinical trials and...
-
No emicizumab this year for non-inhibitor patients
Montreal, April 17, 2020 – The Canadian Hemophilia Society (CHS) has learned that emicizumab (Hemlibra) will not become available for those with hemophilia A without...